Inovio Pharmaceuticals (INO) on Tuesday announced “positive” interim clinical data results of INO-4800, its experimental vaccine candidate against the novel coronavirus.Shares, however dropped 12% to $27.74 in midday U.S. trading, suggesting investors were taking the results with a grain of salt. The value of the stock has this year already ballooned 740%.Inovio said that the early-stage clinical data demonstrated that INO-4800 resulted in immune responses and was generally safe and well-tolerated in all participants in the first two Phase 1 trial cohorts. In addition, the biotech company announced that INO-4800 has been selected to participate in a non-human primate (NHP) challenge study as part of the U.S. government's Operation Warp Speed, a national program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021."We are very encouraged by the positive interim safety and preliminary cellular and humoral immune response results to date as well as the inclusion...
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]...
Facebook has seen a wave of big name advertisers put their buying on hold. But Facebook's business model shields them from too much damage even if big business opts out....
Lam Research jumped Tuesday, momentarily moving past a 325.22 cup-with-handle buy point. Probably already actionable from downward-sloping trend line. Blue Dot Special – stocks with RS at new high that haven't broken out....
